Ipsen: European approval for Xermelo.
(CercleFinance.com) - The pharmaceutical laboratory Ipsen yesterday announced that the European Commission has approved the marketing of its drug Xermelo "for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy".
"Xermelo complements our strategy for neuroendocrine tumors aiming to deliver clinical benefits along every step of the patient treatment journey," CEO David Meek said.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
"Xermelo complements our strategy for neuroendocrine tumors aiming to deliver clinical benefits along every step of the patient treatment journey," CEO David Meek said.
Copyright (c) 2017 CercleFinance.com. All rights reserved.